FDA inspection
Shandong Anxin Pharmaceutical Co., Ltd. (Laoling site): FDA inspection ending Mar 14, 2025
FDA inspection 1264015 · Voluntary Action Indicated (VAI) · Dezhou
Key facts
| Inspection ID | 1264015 |
|---|---|
| Firm | Shandong Anxin Pharmaceutical Co., Ltd. (Laoling site) |
| FEI number | 3023338181 |
| Address | Circular Economy Demonstration Park |
| City | Dezhou |
| Country | China |
| Fiscal year | 2025 |
| Inspection end date | Mar 14, 2025 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data